Printer Friendly

WYETH-AYERST LABORATORIES ACQUIRES PRENATAL VITAMIN LINE FROM ICI PHARMACEUTICALS GROUP

 WYETH-AYERST LABORATORIES ACQUIRES PRENATAL VITAMIN LINE
 FROM ICI PHARMACEUTICALS GROUP
 PHILADELPHIA, Oct. 15 /PRNewswire/ -- Wyeth-Ayerst Laboratories has acquired Stuart Prenatal(R) and Stuartnatal(R) 1+1, Multivitamin/ Multimineral Supplements for expectant and lactating mothers.
 The acquisition, which became effective Sept. 8, was announced jointly today by Wyeth-Ayerst Laboratories and ICI Pharmaceuticals Group of Wilmington, Del., who developed and previously marketed the products.
 In the United States, three-fourths of pregnant women visit their doctors during the first trimester of pregnancy and more than 90 percent receive a prescription for prenatal vitamins during the first visit. Prenatal care represents the greatest activity in most ob/gyn offices. Stuartnatal 1+1 is available with a doctor's prescription; Stuart Prenatal is available over the counter.
 "Stuart Prenatal and Stuartnatal 1+1 are excellent products and have established their strength in the market over many years," said Fred Hassan, president of Wyeth-Ayerst Laboratories. "As a leader in both female health care and pediatric products, we know that this product line is a strong complement to our presence in the prenatal care area and will enhance our competitive advantage." Stuartnatal 1+1 and Stuart Prenatal will be marketed through the Wyeth Pediatrics Division and sold through the combined Female Healthcare and Pediatrics sales forces.
 Wyeth-Ayerst Laboratories continues to expand its commitment to the health care of women, infants and children. "Our comprehensive product line, which continues to grow, is supported by patient education information, such as the Family Ways program for expectant mothers, available only through healthcare professionals," Hassan said.
 "Our decision to sell the prenatal vitamin line is in concert with our strategic plan to concentrate research and development as well as sales and marketing efforts in key therapeutic areas including cardiovascular, infectious and respiratory disease, central nervous system disorders, oncology and anesthesiology," said Robert C. Black, president, ICI Pharmaceuticals Group.
 Wyeth-Ayerst, a division of American Home Products Corporation (NYSE: AHP), is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular and metabolic disease therapies, central nervous system drugs, anti- inflammatory agents, vaccines and infant nutritionals. American Home Products Corporation is a worldwide manufacturer and marketer of prescription drugs, medical supplies and diagnostic equipment, over-the- counter medicines and food products.
 ICI Pharmaceuticals Group, which includes ICI Pharma and Stuart Pharmaceuticals, is a business unit of ICI Americas Inc., the U.S. subsidiary of U.K.-based ICI PLC (NYSE: ICI). In the 50 years since the company was founded, ICI has earned an outstanding reputation as an innovative research-intensive company dedicated to the highest standards of pharmaceutical discovery, development and production. ICI Pharmaceuticals Group has approximately 3,000 employees, including some 800 of whom are engaged in research, development and quality assurance, and a sales force of 1,000 representatives.
 /delval/
 -0- 10/15/92
 /CONTACT: Audrey Ashby of Wyeth-Ayerst, 215-971-5823; or Anne Rogers of Parallax Communications, 317-638-7898, for Wyeth-Ayerst; or Mark Sahl of ICI, 302-886-7859/ CO: Wyeth-Ayerst Laboratories; ICI Pharmaceuticals Group; American Home
 Products Corporation; Imperial Chemical Industries PLC ST: Pennsylvania, Delaware IN: MTC SU:


MK-LJ -- PH003 -- 0236 10/15/92 09:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 15, 1992
Words:517
Previous Article:THRIFTY TEL INC. REPORTS FINANCIAL RESULTS FOR THE YEAR ENDED MAY 31, 1992
Next Article:LINTRONICS TECHNOLOGIES SIGNS A-MED AS MEDICAL EQUIPMENT DEALER FOR SALE OF PRODUCTS
Topics:


Related Articles
AMERICAN HOME PRODUCTS CORP. AND KAKEN PHARMACEUTICAL ANNOUNCE GROWTH HORMONE LICENSING AGREEMENT
WYETH-AYERST LABORATORIES RESPONDS TO SENATE AGING COMMITTEE REPORT
HASSAN NAMED GROUP V.P./GLOBAL PHARMACEUTICALS OF AMERICAN HOME PRODUCTS CORPORATION; ESSNER SUCCEEDS HASSAN AS WYETH-AYERST PRESIDENT
WYETH-AYERST LABORATORIES AWARDS PHYSICIANS FOR SIGNIFICANT PROFESSIONAL ACHIEVEMENT
FDA ADVISORY COMMITTEE RECOMMENDS CLEARANCE OF OBESITY DRUG
FDA CLEARS ZOSYN FOR NOSOCOMIAL PNEUMONIA
Wyeth-Ayerst Laboratories Announces Final Stage In Phase-Out of U.S. Infant Formula Product Line
FDA Decision Recognizes Complexity of Premarin(R) (conjugated estrogens tablets, USP)
Wyeth-Ayerst Laboratories Offers Training Program to Help Florida Pharmacists Improve Health Care for Women in their Communities
Wyeth-Ayerst States it Acted Responsibly With Diet Drugs

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters